Sandoz announces US FDA approval and launch of Glatopa(R) 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis

Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched in the US in June 2015, will offer patients a compl... Biopharmaceuticals, Generics, FDA, Product Launch Sandoz, Novartis, Glatopa, glatiramer, Copaxone, multiple sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news